

13.00% p.a. Callable Barrier Reverse Convertible on AbbVie Inc, Eli Lilly, Pfizer

Final Terms

SSPA Designation

Barrier Reverse Convertible (1230)

Contact

+41 58 283 59 15

<https://markets.vontobel.com/>

In Switzerland, these financial instruments are considered structured products. They are not collective investment schemes within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA), and are therefore not subject to the regulations of the CISA or the supervision of the Swiss Financial Market Supervisory Authority FINMA. The investors bear the Issuer's credit risk.

Summary

This summary constitutes an introduction to the Prospectus. Investment decisions must not be based on the introduction but on the information contained in the entire Prospectus. The issuer accepts no liability for the summary unless the summary itself is misleading, incorrect or contradictory when read together with the other parts of the Prospectus.

Important information on the Securities

Issuer	Bank Vontobel AG, Zurich (Moody's Long Term Deposit Rating: Aa3)
Lead Manager	Bank Vontobel AG, Zurich
ISIN / Swiss Security Number / Symbol	CH1512034609 / 151203460 / RMB8YV
SSPA Designation	Barrier Reverse Convertible (1230), see also www.sspa.ch
Initial Fixing	02 July 2026
Payment Date	09 July 2026
Final Fixing	03 January 2028
Repayment Date	10 January 2028
Redemption / Delivery	see "Redemption / Delivery" below
Underlyings	AbbVie Inc, Registered Share Eli Lilly & Co., Registered Share Pfizer Inc., Registered Share
Settlement	Cash payment and/or physical settlement

Important information on the offer and admission to trading

Issue Price	100.00% of the Nominal Value
Nominal Value	USD 2'000.00
Issue size	USD 25'000'000, with the option to increase
Minimum investment	USD 2'000.00 Nominal Value
Public offer start	22 June 2026
Public offer end	The public offer of the Securities will end either at expiry of the term of the Securities or – unless a subsequent Base Prospectus has been approved and published by the final day of validity of a Base Prospectus – at expiry of the Base Prospectus in accordance with article 55 FINSA
Type of offering	Public offer in Switzerland: the Final Terms being submitted to and published by the regulator, SIX Exchange Regulation
Restrictions on sale	USA, US Persons / EEA / United Kingdom / Dubai/DIFC; see the Base Prospectus for other restrictions on sale
Listing / Admission to trading	Will be applied for in the main segment at the SIX Swiss Exchange.
Secondary market trading	The Issuer or Lead Manager intend, under normal market conditions, to provide a secondary

market throughout the entire term, but do not assume any legal obligation to do so. Indicative daily prices of this product are available at <https://markets.vontobel.com>.

Product Description

These products are characterised by one or several guaranteed Coupons, several Barriers as well as by a – albeit only conditional – redemption at the Nominal Value. The Issuer has the right for Early Redemption as further described in "Early Redemption". Provided that no Early Redemption has taken place, the redemption at the end of the term is determined on the basis of the performance and the closing prices of the respective Underlyings: A redemption at the Nominal Value is guaranteed as long as no Barrier Event has occurred. If a Barrier Event has occurred but at Final Fixing all Underlyings are again higher than or equal to the respective Strike Prices, the Nominal Value is repaid. If, however, a Barrier Event has occurred and at Final Fixing at least one of the Underlyings closes lower than the corresponding Strike Price, the investor receives the delivery of the Underlying with the poorest performance or a cash compensation, corresponding to the closing price of this Underlying (for details see "Redemption/Delivery").

Product Conditions

ISIN / Swiss Security Number / Symbol	CH1512034609 / 151203460 / RMB8YV
Issue Price	100.00% of the Nominal Value
Nominal Value	USD 2'000.00
Reference Currency	USD; issue, trading and redemption are in the Reference Currency
Initial Fixing	02 July 2026 Eli Lilly & Co.: 02 July 2026, closing price Pfizer Inc.: 02 July 2026, closing price AbbVie Inc.: 02 July 2026, closing price
Payment Date	09 July 2026
Last Trading Day	03 January 2028 (12:00 PM, local time Zurich)
Final Fixing	03 January 2028; Closing price on the Reference Exchange
Repayment Date	10 January 2028
Underlyings	AbbVie Inc. (further details on the Underlying see below) Initial Reference Price USD 261.07 Strike Price USD 261.07 (100.00%*) Barrier USD 143.59 (55.00%*) Number of Underlyings 7.66078 (fractions are paid out in cash, no accumulation) * in % of the Initial Reference Price Eli Lilly & Co. (further details on the Underlying see below) Initial Reference Price USD 1'213.91 Strike Price USD 1'213.91 (100.00%*) Barrier USD 667.65 (55.00%*) Number of Underlyings 1.64757 (fractions are paid out in cash, no accumulation) * in % of the Initial Reference Price Pfizer Inc. (further details on the Underlying see below) Initial Reference Price USD 24.32 Strike Price USD 24.32 (100.00%*) Barrier USD 13.38 (55.00%*) Number of Underlyings 82.23684 (fractions are paid out in cash, no accumulation) * in % of the Initial Reference Price
Barrier Monitoring	06 July 2026 (from 15:30 (local time Zurich) at the earliest) until 03 January 2028, continuous monitoring
Barrier Event	A Barrier Event shall be deemed to occur if during the Barrier Monitoring the price of at least one of the Underlyings is at or below the respective Barrier Level.
Coupon	13.0000% p.a. (payments according to "Coupon Payment(s)")
Business Day Convention	Modified Following, Unadjusted If a Repayment Date or a Coupon Payment Date (each a "Relevant Payment Date") is not a Bank Business Day, the Relevant Payment Date shall be the next Bank Business Day, unless the Relevant Payment Date would therefore fall into the next calendar month, in this case the Relevant Payment Date shall be the immediately preceding Bank Business Day. The Coupon due on the Relevant Payment Date and, if applicable, the subsequent Coupon shall not be adjusted accordingly in the event of a postponement of a Relevant Payment Date.

Coupon Payment(s)	Quarterly, subject to Early Redemption			
Coupon Payment Dates	Coupon Payment Dates	Coupon	Interest Component	Premium Component
	13 October 2026	3.2500%	0.9980%	2.2520%
	11 January 2027	3.2500%	0.9980%	2.2520%
	12 April 2027	3.2500%	0.9980%	2.2520%
	12 July 2027	3.2500%	0.9980%	2.2520%
	12 October 2027	3.2500%	0.9980%	2.2520%
	10 January 2028	3.2500%	0.9980%	2.2520%
Early Redemption	At each Monitoring Date, the Issuer has the right but not the obligation, to terminate the product and repay on the next Early Payment Date. The redemption is made at the Nominal Value, plus one last coupon for the corresponding period, provided that the relevant conditions are met (details see "Coupon Payments"). No further payments are made.			
Early redemption monitoring	Monitoring dates	Early Payment Dates		
	02 July 2027	12 July 2027		
	04 October 2027	12 October 2027		
Redemption / Delivery	Provided that no Early Redemption has been made (Details see "Early Redemption"), the following rule is applied on the Final Fixing date: - If no Barrier Event has occurred, at Repayment Date the Nominal Value is repaid - in addition to the Coupon. - If, however, a Barrier Event has occurred, repayment is as follows: 1. If at Final Fixing all closing prices of the Underlyings are higher than or equal to the corresponding Strike Price, the Nominal Value is repaid. In addition, the Coupon is paid out at Repayment Date. 2. If the Final Fixing of at least one Underlying is lower than the corresponding Strike Price, the investor receives a physical delivery of the indicated Number of the Underlying with the poorest performance; fractions are not accumulated and are paid out in cash. In addition, the Coupon is paid out at Repayment Date.			
Parties				
Issuer	Bank Vontobel AG, Zurich (Moody's Long Term Deposit Rating: Aa3)			
Lead Manager	Bank Vontobel AG, Zurich			
Paying and Calculation Agent	Bank Vontobel AG, Zurich			
Supervision	Bank Vontobel AG is authorized as a bank in Switzerland and is subject to prudential supervision by the Federal Financial Markets Regulator FINMA.			
Costs and Charges				
Distribution charges	The Issue Price includes Distribution charges of up to 0.34% p.a. Distribution charges may be paid as a discount on the Issue Price or as a one-time and/or periodic payment to one or more financial intermediaries.			
Further Information				
Issue size	USD 25'000'000, with the option to increase			
Title	The products are issued in the form of uncertificated securities of the Issuer and registered as intermediated securities (<i>Bucheffekten</i>) pursuant to the Federal Intermediated Securities Act, FISA. No certificates, no title imprint.			
Depository	SIX SIS AG			
Clearing / Settlement	SIX SIS AG, Euroclear Brussels, Clearstream (Luxembourg)			
Applicable Law / Jurisdiction	Swiss law / Zurich 1, Switzerland			
Publication of notices and adjustments	All notices to investors concerning the products and adjustments to the product terms (e.g. due to corporate actions) are published under the "Product history" of the respective product at https://markets.vontobel.com . In the case of products listed at SIX Swiss Exchange notifications are published at www.six-swiss-exchange.com in accordance with applicable rules, too.			
Early Termination	The Issuer has the right for Early Redemption as further described in "Early Redemption". Furthermore only for fiscal or other extraordinary reasons, as well as in case of no outstanding positions (as specified in detail in the Base Prospectus).			
Secondary market trading	The Issuer or Lead Manager intend, under normal market conditions, to provide a secondary market throughout the entire term, but do not assume any legal obligation to do so. Indicative daily prices of this product are available at https://markets.vontobel.com .			
Price setting	Secondary market price quotations are "dirty", that is, accumulated interest is included.			
Listing / Admission to trading	Will be applied for in the main segment at the SIX Swiss Exchange.			
Minimum investment	USD 2'000.00 Nominal Value			
Minimum trading lot	USD 2'000.00 Nominal Value			

Tax treatment in Switzerland

Swiss Income Tax	This product does not qualify for predominantly one-off interest payments (Non-IUP). The coupons consist of two components: the premium component, which in Switzerland qualifies as a tax-free capital gain, and the interest component, which in Switzerland is subject to direct federal tax (maturity principle).
Swiss Withholding Tax	The interest component of the coupon is subject to withholding tax.
Swiss Turnover Tax	Secondary market transactions are subject to the swiss turnover tax (TK22). If delivery of the underlying is stipulated, the swiss turnover tax may be imposed as well.
General Information	Transactions and payments relating to this product may be subject to further (foreign) transaction taxes, duties and/or withholding taxes, in particular a withholding tax pursuant to the Section 871(m) of the US Internal Revenue Code. All payments from this product will occur with any applicable taxes and duties deducted. If delivery of the underlying is stipulated, foreign taxes and duties have to be assumed by the investors. The taxation mentioned is a non-binding and non-exhaustive summary of the applicable treatment of Swiss-domiciled private investors for tax purposes. The investor's specific circumstances, however, are not taken into account. We point out that Swiss and/or foreign tax law or the authoritative practice of Swiss and/or foreign tax authorities can change at any time or specify further tax or charge liabilities (possibly even with retrospective effect). Potential investors should have the tax effects of the purchase, holding, sale or repayment of this product examined by their own tax adviser - especially with respect to the effects of taxation under another jurisdiction.

Description of the Underlying

Pfizer Inc.	Name and type: Pfizer Inc., Registered Share Company and place of registration: Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA Identification: ISIN US7170811035 / Bloomberg <PFE UN Equity> Reference Exchange: NYSE Futures exchange: Chicago Board Options Exchange; the Calculation Agent can determine another futures exchange at its discretion Performance: Available at www.nyse.com Transferability: According to the articles of incorporation of Pfizer Financial statements: Available at www.pfizer.com
Eli Lilly & Co.	Name and type: Eli Lilly & Co., Registered Share Company and place of registration: Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, United States Identification: ISIN US5324571083 / Bloomberg <LLY UN Equity> Reference Exchange: NYSE Futures exchange: Chicago Board Options Exchange; the Calculation Agent can determine another futures exchange at its discretion Performance: Available at www.nyse.com Transferability: According to the articles of incorporation of Eli Lilly Financial statements: Available at www.lilly.com
AbbVie Inc	Name and type: AbbVie Inc, Registered Share Company and place of registration: AbbVie Inc, 1 North Waukegan Road, North Chicago, IL 60064, USA Identification: ISIN US00287Y1091 / Bloomberg <ABBV UN Equity> Reference Exchange: NYSE Futures exchange: Chicago Board Options Exchange; the Calculation Agent can determine another futures exchange at its discretion Performance: Available at www.nyse.com Transferability: According to the articles of incorporation of AbbVie Inc Financial statements: Available at www.abbvie.com

Prospects of Profit and Losses

Any possible gain results from the guaranteed fixed Coupons. Nevertheless, there is an upper limit to the gain, as the maximum payment is the Nominal Value plus the coupons.

The Issuer has the right to terminate the product prematurely (for details see "Early Redemption").

These products have only conditional repayment at the Nominal Value defined by the individual Barriers: If a Barrier Event has occurred, the right of

a guaranteed repayment at the Nominal Value ceases to apply immediately. Investors should be aware that this can happen during the relevant Barrier Monitoring (period of time or point(s) of time). Accordingly, the risks are considerable; given upwardly limited chances of gains, they correspond largely to the risks of a direct investment in the Underlying with the poorest performance. The lower the closing price of the Underlying with the poorest performance after falling below its Strike Price, the greater the losses sustained. Apart from the Coupon Payments, in extreme cases, i.e. when the price of the Underlying is equal to zero (0), the maximum loss can lead to a loss of all the capital invested. Even if the performance of the Underlyings is positive and no Barrier Event has occurred, the price of the product during the term can be considerably below the Issue Price. Potential investors should bear in mind that price changes to the Underlyings, as well as other influencing factors, may have a negative effect on the value of products.

Significant Risks for Investors

Currency risks

If the Underlying or Underlyings is/are denominated in a currency other than the product's Reference Currency, investors should bear in mind that this may involve risks due to fluctuating exchange rates and that the risk of loss does not only depend on the performance of the Underlying(s) but also on any unfavourable performance of the other currency or currencies. This does not apply for currency-hedged products (quanto structure).

Market risks

The general market performance of Securities is dependent in particular on the development of the capital markets which, for their part, are influenced by the general global economic situation as well as by the economic and political framework conditions in the respective countries (so-called market risk). Changes to market prices such as interest rates, commodity prices or corresponding volatilities may have a negative effect on the valuation of the Underlying(s) or the product.

Disruption risks

There is also the risk of market disruptions (such as trading or stock market interruptions or discontinuation of trading) or other unforeseeable occurrences concerning the respective Underlyings and/or their stock exchanges or markets taking place during the term or upon maturity of the products. Such occurrences can have an effect on the time of redemption and/or on the value of the products.

In the event of trading restrictions, sanctions and similar occurrences, the Issuer is entitled, for the purpose of calculating the value of the product, to include at its own discretion the Underlying instruments at their most recently traded price, at a fair value to be established at its sole discretion or indeed as worthless, and/or additionally to suspend pricing in the product or liquidate the product prematurely.

Secondary market risks

Under normal market conditions, the Issuer or the Lead Manager intend to post bid- and ask-prices on a regular basis. However, neither the Issuer nor the Lead Manager is under any obligation with respect to investors to provide such bid- and ask-prices for specific order or securities volumes, and there is no guarantee of a specific liquidity or of a specific spread (i.e. the difference between bid- and ask-prices), for which reason investors cannot rely on being able to purchase or sell the products on a specific date or at a specific price.

Issuer risk

The value of Structured Products may depend not only on the performance of the Underlying(s), but also on the creditworthiness of the Issuer, which may change during the term of the Structured Product. The investor is exposed to the risk of default of the Issuer. For further information on the rating of Bank Vontobel AG, please see the Base Prospectus.

Risks relating to potential conflicts of interest

There may be conflicts of interest at the Vontobel Group companies that could have a negative impact on the value of the Structured Products. For example, Vontobel Group companies may enter into or participate in trading and hedging transactions relating to the Underlying. They may also perform other functions relating to the Structured Products (e.g. as Calculation Agent, Index Sponsor and/or Market Maker) which enable them to determine the composition of the Underlying or calculate its value. Vontobel Group companies may also receive non-public information relating to the Underlying. It should also be noted that the payment of distribution fees and other commissions to financial intermediaries could result in conflicts of interest to the detriment of the investor, as this could create an incentive for the financial intermediary to distribute products with a higher commission preferentially to its clients. As market maker, Vontobel Group companies can determine the price of Structured Products themselves to a large extent and determine it on the basis of various factors and earnings considerations. Please also note the further, detailed description of potential conflicts of interest and their impact on the value of the Structured Products as contained in the Base Prospectus.

Selling Restrictions

Any products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this product may apply in other jurisdictions. Investors in this product should seek specific advice before on-selling this product.

United States, U.S. persons

The securities neither have been nor will be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and the securities may neither be offered nor sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

Trading in the securities has not been and will not be approved by the United States Commodity Futures Trading Commission under the United States Commodity Exchange Act or by any other state securities commission nor has the Commodity Futures Trading Commission or any other

state securities commission passed upon the accuracy or the adequacy of the Base Prospectus. The Base Prospectus may not be used in the United States and may not be delivered in the United States.

The securities will not be directly or indirectly offered, sold, traded or delivered within the United States or to or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act).

Each offeror is required to agree that it will not offer or sell the securities as part of their distribution at any time within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

The term "United States" as used herein means the United States of America, its territories or possessions, any state of the United States, the District of Columbia or any other enclave of the United States government, its agencies or instrumentalities.

European Economic Area (EEA)

In relation to each Member State of the European Economic Area any offeror of Securities represents and agrees that it has not made and will not make an offer of the Securities which are the subject of the offering contemplated by this Base Prospectus as completed by the Final Terms to the public in that Member State other than at any time:

- (a) to persons who are qualified investors as defined in the Prospectus Regulation;
- (b) to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the Lead Manager for any such offer; or
- (c) in any other circumstances falling within Articles 1(3), 1(4) and/or 3(2)(b) of the Prospectus Regulation,

provided that no such offer of Securities shall require the Issuer or Lead Manager to publish a prospectus pursuant to Article 3 of the Prospectus Regulation.

For the purposes of the provision above, the expression an "offer of securities to the public" in relation to any securities in any Member State means the communication in any form and by means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129, and includes any relevant implementing measure in the relevant Member State.

United Kingdom

With respect to the United Kingdom, each person offering the securities must represent and agree that it has not made and will not make an offer of securities to the public in the United Kingdom that are the subject of this Base Prospectus, except that an offer of such securities in the United Kingdom may be made:

- (a) in relation to any products which have a maturity of less than one year, (i) it is a person whose ordinary activities involve it in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of its business and (ii) it has not offered or sold and will not offer or sell any products other than to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or as agent) for the purposes of their businesses or who it is reasonable to expect will acquire, hold, manage or dispose of investments (as principal or agent) for the purposes of their businesses where the issue of the products would otherwise constitute a contravention of section 19 of the Financial Services and Markets Act 2000 ("FSMA") by the Issuer;
- (b) to fewer than 150 natural or legal persons (other than qualified investors as defined in paragraph 15 of Schedule 1 of the POATRs), subject to obtaining the prior consent of the relevant dealer or dealers nominated by the issuer for such offer; or
- (c) in any other circumstances falling within Part 1 of Schedule 1 of the POATRs.

For the purposes of this provision, the expression "offer of securities to the public" in relation to the notes in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for such securities. The expression "POATRs" means the Public Offers and Admissions to Trading Regulations 2024.

Furthermore, each distributor of securities issued under this Base Prospectus must represent and agree, in respect of the securities, that it:

- (a) is a person whose ordinary activities involve acquiring, holding, managing or disposing of investments (as principal or agent) for business purposes and it has offered or sold and will offer or sell the securities only to persons whose ordinary activities involve acquiring, holding, managing or disposing of investments (as principal or agent) for business purposes or who it is reasonable to expect will acquire, hold, manage or dispose of investments for business purposes (as principal or agent), where the issue of the securities would otherwise constitute a contravention of Article 19 FSMA by the issuer;
- (b) has communicated or caused to be communicated and will communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of Article 21 of the FSMA) received by it in connection with the issue or sale of the securities only in circumstances in which Article 21(1) of the FSMA does not apply to the issuer or the guarantor; and
- (c) has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom.

DIFC/Dubai

This document relates to an Exempt Offer in accordance with the Markets Rules Module (MKT) of the Dubai Financial Services Authority (DFSA).

This document is intended for distribution only to a person entitled to receive it under Rule 2.3.1 of the MKT. It must not be delivered to, or relied on, by any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this document nor taken any steps to verify the information set out in it, and has no responsibility for it. The securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this document, you should consult an authorized financial adviser.

Further risk information and selling restrictions

Please also note the additional risk factors and selling restrictions set out in detail in the Base Prospectus.

Legal Notices

Product documentation

This document ("Final Terms") contains the final terms for the product. The Final Terms, together with the "Vontobel Swiss Base Prospectus for the Issue of Securities" in the currently valid version ("Base Prospectus"), which are written in German (foreign language versions represent non-binding translations), represent the entire documentation for this product (the "Prospectus") and accordingly the Final Terms should always be read in conjunction with the Base Prospectus and any supplements thereto. Definitions used in the Final Terms but not defined herein have the meanings given to them in the Base Prospectus. In the event of any conflict between these Final Terms and the Base Prospectus, the provisions of the Final Terms shall prevail. The Issuer and/or Bank Vontobel AG is entitled at any time to correct typographical or arithmetic errors or other obvious errors in these Final Terms and conditions and to make editorial changes as well as to change or add to contradicting or incomplete provisions without the consent of the investors. The issuer has no obligation to issue the product. The Prospectus can be obtained from Bank Vontobel AG, Structured Products Documentation, Bleicherweg 21, 8002 Zurich, Switzerland (Telephone: +41 58 283 59 15) and can also be accessed on the website <https://markets.vontobel.com>. Vontobel expressly disclaims any liability for publications on other Internet platforms. Notifications in connection with this product will be rendered legally valid upon their publication as described in the Base Prospectus. When replacing the Base Prospectus with a successive version of the Base Prospectus, the Final Terms must be read together with the most recent valid successive version of the Base Prospectus (in each case, a "Successive Base Prospectus"), which either (i) replaced the Base Prospectus, or (ii) if one or more Successive Base Prospectuses to the Base Prospectus have already been published, the most recently published Successive Base Prospectus and the term Prospectus must be interpreted accordingly. The Issuer consents to the use of the Base Prospectus (including any subsequent Base Prospectuses) together with the respective Final Terms in connection with a public offer of the products by a financial intermediary who is authorised to make such offers.

Further information

The list and information shown do not constitute a recommendation concerning the Underlying in question; they are for information purposes only and do not constitute either an offer or an invitation to submit an offer, or a recommendation to purchase Financial Products. Indicative information is provided without warranty. The information is not a substitute for the advice that is indispensable before entering into any derivative transaction. Only investors who fully understand the risks of the transaction to be concluded and who are commercially in a position to bear the losses which may thereby arise should enter into such transactions. Furthermore, we refer to the brochure "Risks Involved in Trading Financial Instruments" which you can order from us. In connection with the issuing and/or selling of Structured Products, companies from the Vontobel Group can pay reimbursements to third parties directly or indirectly in different amounts (Details see "Costs and Charges"). Such commission is included in the issue price. You can obtain further information from your sales agent upon request. We will be happy to answer any questions you may have concerning our products on +41 58 283 59 15 from 08.00 – 17.00 CET on bank business days. Please note that all calls to this number are recorded. By calling this number, your consent to such recording is deemed given.

Material changes since the most recent annual financial statements

Subject to the information in these Final Terms and the Base Prospectus, no material changes have occurred in the assets and liabilities, financial position and profits and losses of the Issuer resp. Guarantor since the reporting date or the close of the last financial year or the interim financial statements of the Issuer and, as the case may be, of the Guarantor.

Responsibility for the Prospectus

Bank Vontobel AG takes responsibility for the content of the Prospectus and hereby declares that, to the best of its knowledge, the information is correct and that no material facts or circumstances have been omitted.

Zurich, 02 July 2026 / Deritrade-ID: 6037221558

Bank Vontobel AG, Zurich

Your customer advisor will be happy to answer any questions you may have.

Bank Vontobel AG
Gotthardstrasse 43, CH-8022 Zurich
Telephone +41 58 283 71 11
<https://markets.vontobel.com/>

Banque Vontobel SA
Rue du Rhône 31, CH-1204 Genève
Téléphone +41 58 283 26 26
<https://markets.vontobel.com/>